Swiss pharmaceutical giant Novartis AG raised its full-year sales outlook because of delays in generic competition to its blockbuster blood pressure drug Diovan even though it said negative currency trends contributed to a 6 percent drop in its third-quarter net profit.
The Basel, Switzerland-based company said Tuesday that it made a net profit of $2.26 billion in the July-September quarter, down from last year's equivalent of $2.42 billion, which was downwardly adjusted to conform to new reporting requirements.
Novartis said a weaker yen and falls in emerging market currencies, along with expiring patents and royalty payments, affected its financial performance. Even so, third-quarter sales rose 4 percent to $14.3 billion.
"Novartis delivered strong sales performance in the third quarter, with all divisions contributing to growth," Chief Executive Joseph Jimenez said in the statement.
The company noted that its patent rights on Diovan expired in the United States last year, but U.S. regulators have yet to approve the generic version from competitor Ranbaxy Laboratories.
Because of that delay and what it called "strong growth products momentum," Novartis said it now expects group sales in 2013 to rise in the low- to mid-single digit range if currencies stay unchanged.
The company said it expects generic competition to cut into its sales by $2.3 billion in 2013, which is more than $1 billion less than the level it expected at the start of the year, "mostly due to the continued absence of generic competition for Diovan monotherapy in the U.S."
Explore further: Novartis Q4 net profit rebounds to $2.1 billion
© 2013 The Associated Press. All rights reserved.
Medical Xpress on facebook
Related Stories
Novartis Q4 net profit rebounds to $2.1 billion
Jan 23, 2013
(AP)—Swiss drug maker Novartis AG reported a jump in fourth-quarter net profit to $2.08 billion on Wednesday, citing the lack of a $900-million one-time charge it took in the same period the previous year.
Novartis lifts sales outlook despite Q2 profit dip
Jul 17, 2013
(AP)—Swiss pharmaceutical company Novartis AG raised its sales outlook for the full year on Wednesday, despite posting a 5 percent net income drop in the second quarter.
Toshiba swings to profit as devices sell well
Jul 31, 2013
Japan's Toshiba on Wednesday reported $54 million in net profit for the April-June quarter, reversing a quarterly loss a year earlier, thanks to a weak yen and brisk sales of electronic devices.
SAP profits up 23 percent as cloud computing grows
Oct 21, 2013
Business management software company SAP AG says net profit rose 23 percent in the third quarter as its cloud computing business grew rapidly and the company kept down costs by holding down hiring of new employees.
New drugs shore up Novartis in Q2
Jul 19, 2012
(AP) — Swiss pharmaceutical company Novartis AG reported a net profit of $2.73 billion during the second quarter, as new drugs and acquisitions offset patent expirations, lower sales of generic medicines ...
Recommended for you
Uruguay to start selling marijuana next year: official
10 hours ago
Uruguay is planning to start selling marijuana legally next year, a top official said, though the Senate must still approve the proposed legislation.
Researchers, pharma experts offer recommendations to expand access to clinical trial data
11 hours ago
A new report by researchers from Harvard University and others in a working group convened by the Multi-Regional Clinical Trials Center (MRCT) at Harvard proposes recommendations for addressing a problem that has vexed drug ...
Family decides when to cut off life support: Canada court (Update)
Oct 18, 2013
Family, not doctors, should decide when to cut off life support, the Supreme Court of Canada ruled Friday in the case of a severely-brain damaged man.
Med students value 'enjoying work' in specialty selection
Oct 17, 2013
(HealthDay)—For first year medical students, enjoying work is the most important lifestyle domain in choosing a specialty, according to a study published in the October issue of Academic Medicine.
Harvard's Wyss Institute and AstraZeneca announce collaboration on Organs-on-Chips for drug safety
Oct 16, 2013
Today the Wyss Institute for Biologically Inspired Engineering at Harvard University and AstraZeneca announced a collaboration that will leverage the Institute's Organs-on-Chips technologies to better predict ...
New estimates give updated count of Iraq war deaths between 2003 and 2011
Oct 15, 2013
During the U.S.-led invasion and occupation of Iraq from 2003 to 2011, for every three people killed by violence, two died as a result of the collapse of the infrustructure that supports health care, clean ...
User comments
© Medical Xpress 2011-2013, Phys.org network
Swiss pharmaceutical giant Novartis AG raised its full-year sales outlook because of delays in generic competition to its blockbuster blood pressure drug Diovan even though it said negative currency trends contributed to a 6 percent drop in its third-quarter net profit.
The Basel, Switzerland-based company said Tuesday that it made a net profit of $2.26 billion in the July-September quarter, down from last year's equivalent of $2.42 billion, which was downwardly adjusted to conform to new reporting requirements.
Novartis said a weaker yen and falls in emerging market currencies, along with expiring patents and royalty payments, affected its financial performance. Even so, third-quarter sales rose 4 percent to $14.3 billion.
"Novartis delivered strong sales performance in the third quarter, with all divisions contributing to growth," Chief Executive Joseph Jimenez said in the statement.
The company noted that its patent rights on Diovan expired in the United States last year, but U.S. regulators have yet to approve the generic version from competitor Ranbaxy Laboratories.
Because of that delay and what it called "strong growth products momentum," Novartis said it now expects group sales in 2013 to rise in the low- to mid-single digit range if currencies stay unchanged.
The company said it expects generic competition to cut into its sales by $2.3 billion in 2013, which is more than $1 billion less than the level it expected at the start of the year, "mostly due to the continued absence of generic competition for Diovan monotherapy in the U.S."
Explore further: Novartis Q4 net profit rebounds to $2.1 billion
© 2013 The Associated Press. All rights reserved.
Medical Xpress on facebook
Related Stories
Novartis Q4 net profit rebounds to $2.1 billion
Jan 23, 2013
(AP)—Swiss drug maker Novartis AG reported a jump in fourth-quarter net profit to $2.08 billion on Wednesday, citing the lack of a $900-million one-time charge it took in the same period the previous year.
Novartis lifts sales outlook despite Q2 profit dip
Jul 17, 2013
(AP)—Swiss pharmaceutical company Novartis AG raised its sales outlook for the full year on Wednesday, despite posting a 5 percent net income drop in the second quarter.
Toshiba swings to profit as devices sell well
Jul 31, 2013
Japan's Toshiba on Wednesday reported $54 million in net profit for the April-June quarter, reversing a quarterly loss a year earlier, thanks to a weak yen and brisk sales of electronic devices.
SAP profits up 23 percent as cloud computing grows
Oct 21, 2013
Business management software company SAP AG says net profit rose 23 percent in the third quarter as its cloud computing business grew rapidly and the company kept down costs by holding down hiring of new employees.
New drugs shore up Novartis in Q2
Jul 19, 2012
(AP) — Swiss pharmaceutical company Novartis AG reported a net profit of $2.73 billion during the second quarter, as new drugs and acquisitions offset patent expirations, lower sales of generic medicines ...
Recommended for you
Uruguay to start selling marijuana next year: official
10 hours ago
Uruguay is planning to start selling marijuana legally next year, a top official said, though the Senate must still approve the proposed legislation.
Researchers, pharma experts offer recommendations to expand access to clinical trial data
11 hours ago
A new report by researchers from Harvard University and others in a working group convened by the Multi-Regional Clinical Trials Center (MRCT) at Harvard proposes recommendations for addressing a problem that has vexed drug ...
Family decides when to cut off life support: Canada court (Update)
Oct 18, 2013
Family, not doctors, should decide when to cut off life support, the Supreme Court of Canada ruled Friday in the case of a severely-brain damaged man.
Med students value 'enjoying work' in specialty selection
Oct 17, 2013
(HealthDay)—For first year medical students, enjoying work is the most important lifestyle domain in choosing a specialty, according to a study published in the October issue of Academic Medicine.
Harvard's Wyss Institute and AstraZeneca announce collaboration on Organs-on-Chips for drug safety
Oct 16, 2013
Today the Wyss Institute for Biologically Inspired Engineering at Harvard University and AstraZeneca announced a collaboration that will leverage the Institute's Organs-on-Chips technologies to better predict ...
New estimates give updated count of Iraq war deaths between 2003 and 2011
Oct 15, 2013
During the U.S.-led invasion and occupation of Iraq from 2003 to 2011, for every three people killed by violence, two died as a result of the collapse of the infrustructure that supports health care, clean ...
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment